GSK plc Sponsored ADR (GSK)
FDA Approves GSK's Nucala for Expanded Use in COPD
GSK's Nucala wins FDA nod for COPD with eosinophilic phenotype, marking its fifth indication and strengthening its respiratory portfolio.
Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?
Gilead Sciences, Inc. GILD and GSK GSK are pioneers in the human immunodeficiency virus (HIV) treatment space.
GSK or ACAD: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?
GSK's Blood-Cancer Treatment Combinations Approved in Japan
The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.
GSK splashes out $1.2bn up-front for liver treatment still in clinical trials
GSK PLC (LSE:GSK, NYSE:GSK) has struck a deal to acquire a drug to treat and prevent the progression of steatotic liver disease, poised for phase III clinical trials, for up to $2 billion. The disease affects up to 5% of the global population, the FTSE 100 group says, and is an "area of significant unmet medical need with limited treatment options".
GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion
The pharma giant will pay $1.2 billion up-front for efimosfermin, with deal including potential success-based milestone payments of $800 million.
GSK to buy efimosfermin for up to $2 billion
British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine from Boston Pharmaceuticals, for up to $2 billion.
ITeos, GSK discontinue lung cancer therapy development
iTeos Therapeutics and partner GSK said on Tuesday that they terminated the development of their experimental lung cancer therapy after its failure to significantly improve progression free survival in a mid-stage trial.
Glaxo (GSK) Upgraded to Buy: Here's What You Should Know
Glaxo (GSK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
5 Reasons GSK Looks Good
GSK's stock price has significantly outperformed the healthcare sector this year, supported by its healthy Q1 2025 numbers. Both turnover and EPS growth exceeded expectations, and the company's guidance indicates that the stock's forward P/E is competitive too. Additionally, GSK's medium-to-long-term financial prospects look good too, based on the company's latest outlook, which also works in the stock's favour.
Here's Why GSK (GSK) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
